Study of Shoulder Disability Among Patients With Head and Neck Cancer Post-surgery

Share this content:
Researchers are evaluating whether 5 shoulder-related PRO measures are reliable, valid, and appropriate for determining shoulder dysfunction in this setting.
Researchers are evaluating whether 5 shoulder-related PRO measures are reliable, valid, and appropriate for determining shoulder dysfunction in this setting.

Title: Reliability and Validity of Five Shoulder-Specific Patient Reported Outcome Measures for Use in Patients With Head and Neck Cancer1

Principal Investigators: Melissa M. Eden, PT, DPT, OCS, Mayo Clinic

Description: For this questionnaire-based study, researchers are using Rasch analysis to evaluate whether 5 shoulder-related patient-reported outcome (PRO) measures are reliable, valid, and appropriate for determining shoulder dysfunction among patients with head and neck cancer post-surgery.

The study's goal is to determine which PRO measure(s) best provide(s) a defining criterion for shoulder dysfunction after neck dissection surgery.

Most patients aged 18 to 90 years reporting shoulder “discomfort, stiffness, or weakness” post–dissection surgery are eligible.

The primary outcome measures are Disability of the Arm, Shoulder and Hand; QuickDASH; Shoulder and Disability Index; University of Washington Quality of Life Scale; Neck Dissection Impairment Index.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02554968.

Status: This study is open and recruiting patients as of June 15, 2017.

This study is sponsored by the Mayo Clinic.

Reference

  1. Clinicaltrials.gov. Reliability and validity of patient reported outcome measures in head and neck cancer. NCT02554968. https://clinicaltrials.gov/ct2/show/NCT02554968. Accessed June 15, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters